Ziftomenib Maintenance Post Allo-HCT

Inclusion criteria

• 18 years or older.
• Pathologically confirmed diagnosis of acute myeloid leukemia (AML).
• Complete remission (CR) or complete remission with incomplete count recovery (CRi) at screening.
• Complete remission (CR):
• no circulating blasts in peripheral blood and \<5% blasts in bone marrow
• no extramedullary disease
• platelet count ≥100 x 10(9)/L and/or absolute neutrophil count ≥1000/µL
• Complete remission with incomplete count recovery (CRi):
• no circulating blasts in peripheral blood and \<5% blasts in bone marrow
• no extramedullary disease
• platelet count \<100 x 10(9)/L and/or absolute neutrophil count \<1000/µL
• Presence of at least one of the following molecular mutations:
• KMT2A rearrangement
• Eligibility and enrollment will be based on local mutational testing.
• The presence of a KMT2A rearrangement (excluding partial tandem duplication \[PTD\]) at the time of initial diagnosis or any other time thereafter is sufficient.
• Participants may receive additional treatment for AML between consent and transplant.
• NPM1 mutation
• Eligibility and enrollment will be based on local mutational testing.
• For participants being transplanted in CR1, the presence of a NPM1 mutation at screening is necessary for the purposes of eligibility.
• For participants being transplanted in greater than or equal to CR2, the presence of a NPM1 mutation at the time of consent is not necessary for eligibility and its presence at the time of initial diagnosis or any other time thereafter is sufficient.
• Participants may receive additional treatment for AML between consent and transplant.
• Treatment with a menin inhibitor prior to transplant is permitted. However, patients who experienced AML relapse or progression while being treated with a menin inhibitor prior to transplant are ineligible.
• Will undergo first allogeneic HCT for their malignancy.
• Transplantation will be performed with the use of conventional myeloablative (MAC) or reduced intensity conditioning (RIC).
• HCT Donor will be one of the following:
• 5/6 or 6/6 (HLA-A, B, DR) matched related donor
• 7/8 or 8/8 (HLA-A, B, DR, C) matched unrelated donor. Matching in the unrelated setting must be at the allele level.
• Haploidentical related donor, defined as ≥ 3/6 (HLA-A, B, DR) matched
• ≥ 4/6 (HLA-A, B, DR) umbilical cord blood (UCB). Matching in the UCB setting is at the antigen level. Recipients may receive either one or two UCB units. In the case of 2 UCB units, both units must have been at least 4/6 matched with the recipient.
• Any non-investigational GVHD prophylaxis regimen is allowed.
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
• Participants must have normal organ and function as defined below:
• AST (SGOT), ALT (SGPT) and Alkaline phosphatase \< 3x institutional upper limit of normal (ULN)
• Total bilirubin \< 1.5 x institutional ULN (with the exception of subjects with a history of Gilbert's syndrome, for which the total bilirubin must be \< 5 x ULN)
• Calculated creatinine clearance ≥ 30 mL/min (Cockcroft-Gault formula)
• LVEF must be ≥50%, as measured by MUGA scan or echocardiogram.
• Female patients of childbearing potential must have a negative pregnancy test, as measured by serum or urine testing.
• The effects of ziftomenib on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) during the entire study treatment period and through 6 months after the last dose of treatment.
• Ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

• History of other malignancy(ies) unless
• the participant has been disease-free for at least 2 years and is deemed by the investigator to be at low risk of recurrence of that malignancy, or
• the cancer has been deemed indolent with no progression over the last 2 years, and deemed by the investigator to be at low risk for further progression during the course of study and follow-up
• the only prior malignancy was cervical cancer in situ and/or basal cell or squamous cell carcinoma of the skin
• Known diagnosis of active hepatitis B or hepatitis C
• Current or history of congestive heart failure New York Heart Association (NHYA) class 3 or 4, or any history of documented diastolic or systolic dysfunction (LVEF \< 50%, as measured by multigated acquisition (MUGA) scan or echocardiogram)
• Current or history of ventricular or life-threatening arrhythmias or diagnosis of long-QT syndrome
• Systemic uncontrolled infection
• Known dysphagia, short-gut syndrome, gastroparesis, or other condition(s) that limits the ingestion or gastrointestinal absorption of drugs administered orally
• Uncontrolled hypertension (systolic blood pressure \[BP\] \> 180 mmHg or diastolic BP \> 100 mmHg)
• QTc interval (i.e., Friderica's correction \[QTcF\]) ≥ 480 ms or other factors that increase the risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome) at screening
• Uncontrolled intercurrent illness that would limit compliance with study requirements.
• Persons who are pregnant or lactating.